Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
| Autor: | Karim, Fizazi, Howard I, Scher, Arturo, Molina, Christopher J, Logothetis, Kim N, Chi, Robert J, Jones, John N, Staffurth, Scott, North, Nicholas J, Vogelzang, Fred, Saad, Paul, Mainwaring, Stephen, Harland, Oscar B, Goodman, Cora N, Sternberg, Jin Hui, Li, Thian, Kheoh, Christopher M, Haqq, Johann S, de Bono, E, Yu |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male medicine.medical_specialty Population Urology Abiraterone Acetate Placebo chemistry.chemical_compound Double-Blind Method medicine Humans Castration Neoplasm Metastasis education Aged Aged 80 and over education.field_of_study Performance status business.industry Apalutamide Abiraterone acetate Prostatic Neoplasms Middle Aged Interim analysis Surgery Androstadienes Oncology chemistry Docetaxel Cabazitaxel business Orchiectomy medicine.drug |
| Zdroj: | The Lancet. Oncology. 13(10) |
| ISSN: | 1474-5488 |
| Popis: | Background Abiraterone acetate improved overall survival in metastatic castration-resistant prostate cancer at a preplanned interim analysis of the COU-AA-301 double-blind, placebo-controlled phase 3 study. Here, we present the final analysis of the study before crossover from placebo to abiraterone acetate (after 775 of the prespecified 797 death events). Methods Between May 8, 2008, and July 28, 2009, this study enrolled 1195 patients at 147 sites in 13 countries. Patients were eligible if they had metastatic castration-resistant prostate cancer progressing after docetaxel. Patients were stratified according to baseline Eastern Cooperative Oncology Group (ECOG) performance status, worst pain over the past 24 h on the Brief Pain Inventory-Short Form, number of previous chemotherapy regimens, and type of progression. Patients were randomly assigned (ratio 2:1) to receive either abiraterone acetate (1000 mg, once daily and orally) plus prednisone (5 mg, orally twice daily) or placebo plus prednisone with a permuted block method via an interactive web response system. The primary endpoint was overall survival, analysed in the intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT00638690. Findings Of the 1195 eligible patients, 797 were randomly assigned to receive abiraterone acetate plus prednisone (abiraterone group) and 398 to receive placebo plus prednisone (placebo group). At median follow-up of 20·2 months (IQR 18·4—22·1), median overall survival for the abiraterone group was longer than in the placebo group (15·8 months [95% CI 14·8—17·0] vs 11·2 months [10·4—13·1]; hazard ratio [HR] 0·74, 95% CI 0·64—0·86; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|